Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: A randomized study

Clinical Ophthalmology

Volumn 10, Issue , 2016, Pages 1131-1138

  Pece, Alfredo ^a   Allegrini, Davide ^a   Montesano, Giovanni ^b   Dimastrogiovanni, Andreafabio ^a  

^a Melegnano Hospital   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti VEGF therapy; Macular edema; Pressure spikes; Pressure lowering medication

Indexed keywords

RANIBIZUMAB; TIMOLOL;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; EVENING DOSAGE; FEMALE; GEL; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84975296979     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S106096     Document Type: Article

References (42)

1. Lee YJ, Park HJ, Lee TG, et al. Primary combined photodynamic therapy and intravitreal bevacizumab injection for neovascular age-related macular degeneration. J Korean Ophthalmol Soc. 2010;51(1):35-41.
2. Smit DP, Meyer D. Intravitreal bevacizumab: an analysis of the evidence. Clin Ophthalmol. 2007;1(3):273-284.
3. Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):779-784.
4. D’Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006;113(6):992-1001.
5. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthal. 2010;21(3):178-183.
6. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina. 2007;27(8):1044-1047.
7. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42(6):807-811.
8. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930-934.e1.
9. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009;23(1):181-185.
10. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119(2):321-326.
11. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010;26(1):105-110.
12. El Chehab H, Le Corre A, Agard E, et al. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol. 2013;23(3):277-283.
13. Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250(10):1435-1440.
14. Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32(7):1295-1301.
15. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
16. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
17. Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34(Suppl 12):S1-S18.
18. Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18(9):658-661.
19. Mojica G, Hariprasad SM, Jager RD, Mieler WF. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol. 2008;92(4):584.
20. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol. 2012;23(2):105-110.
21. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol. 2003;48(Suppl 1):S17-S20.
22. Michelson G, Groh MJ, Langhans M. Perfusion of the juxtapapillary retina and optic nerve head in acute ocular hypertension. Ger J Ophthalmol. 1996;5(6):315-321.
23. Quigley HA, Anderson DR. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci. 1977;16(7):640-644.
24. Lemos-Reis R, Moreira-Gonçalves N, Melo AB, Carneiro AM, Falcão-Reis FM. Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clin Ophthalmol. 2014;8:1383-1388.
25. Savage JA, Thomas JV, Belcher CD 3rd, Simmons RJ. Extracapsular cataract extraction and posterior chamber intraocular lens implantation in glaucomatous eyes. Ophthalmology. 1985;92(11):1506-1516.
26. Kolker AE. Visual prognosis in advanced glaucoma: a comparison of medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc. 1977;75:539-555.
27. Chang W, Chung M. Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection. Eur J Ophthalmol. 2007;17(5):776-779.
28. Lin JM, Tsai YY, Chiu YT, Hung PT. Paracentesis before or after intravitreal injection of triamcinolone acetonide and its necessity? Am J Ophthalmol. 2006;141(5):985-986.
29. Huang WC, Lin JM, Chiang CC, Tsai YY. Necessity of paracentesis before or after intravitreal injection of bevacizumab. Arch Ophthalmol. 2008;126(9):1314-1315.
30. Ozcaliskan S, Ozturk F, Yilmazbas P, Beyazyildiz O. Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection. Int J Ophthalmol. 2015;8(3):496-500.
31. Murray CD, Wood D, Allgar V, Walters G, Gale RP. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (Lond). 2014;28(10):1218-1222.
32. Kim GN, Han YS, Chung IY, Seo SW, Park JM, Yoo JM. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension. Semin Ophthalmol. 2013;28(2):61-67.
33. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010;128(12):1523-1527.
34. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982; 93(2):232-237.
35. Lai JS, Chua JK, Leung AT, Lam DS. Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation. J Cataract Refract Surg. 2000;26(3):386-391.
36. Quaranta L, Katsanos A, Floriani I, Riva I, Russo A, Konstas AG. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52(10):1552-1557.
37. Byrd S, Singh K. Medical control of intraocular pressure after cataract surgery. J Cataract Refract Surg. 1998;24(11):1493-1497.
38. Haimann MH, Phelps CD. Prophylactic timolol for the prevention of high intraocular pressure after cataract extraction; a randomized, prospective, double-blind trial. Ophthalmology. 1981;88(3):233-238.
39. Kanellopoulos AJ, Perry HD, Donnenfeld ED. Timolol gel versus acetazolamide in the prophylaxis of ocular hypertension after phacoemulsification. J Cataract Refract Surg. 1997;23(7):1070-1074.
40. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010;4:28-29.
41. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246(7):955-958.
42. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012;21(4):241-247.